Skip to main content
Premium Trial:

Request an Annual Quote

Qiagen, HTG Molecular Begin Second CDx Development Project

NEW YORK (GenomeWeb) – Qiagen and HTG Molecular Diagnostics have agreed to a second development program under their previously announced master assay development, commercialization, and manufacturing agreement.

As part of the program announced today, HTG Molecular and Qiagen Manchester, a wholly owned subsidiary of Qiagen, will use HTG EdgeSeq technology to develop gene expression profiling assays for use with next-generation sequencing technology to support an unnamed pharmaceutical company's therapeutic development and commercialization programs.

"We are very pleased with the early results of our partnership with Qiagen and are encouraged by customer reception to our joint capabilities, which provide a complete NGS solution from biomarker development to full companion diagnostic commercialization," HTG President and CEO TJ Johnson said in a statement.

"With two new programs realized from the Qiagen partnership to date, HTG now has three distinct clinical assay development programs underway, including two that we believe could lead to regulatory filings for companion diagnostics during 2018," Johnson added.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.